Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Tele2 in connection with the acquisition of TDC Sverige
Mandate

Vinge advises Tele2 in connection with the acquisition of TDC Sverige

June 21, 2016

Vinge has advised Tele2 Sverige AB in connection with the acquisition of TDC Sverige AB for an enterprise value of SEK 2.9 billion.

In connection with the acquisition, Tele2 intends to perform a rights issue of approximately SEK 3 billion.

The acquisition is conditional upon approval by the relevant competition authorities.

Vinge’s team primarily consisted of partners Johan Winnerblad, Eva Fredrikson and Carl Johan af Petersens together with counsel Matthias Pannier and associates Mathilda Persson, Albert Wållgren, Mika Jordan, Sara Strandberg, Christoffer Nordin and Ludvig Wettergren. Partner Charlotte Levin and associate Amanda Knutsson provided capital markets advice. Partner Johan Karlsson and associate Karl Samuelsson provided competition law advice.

Related

Vinge advises Irisity in connection with issue of units

 Vinge advises Irisity AB (publ) in connection with its rights issue of units consisting of shares and warrants. The issue is guaranteed to 80 per cent through subscription commitments and external guarantors.
October 03, 2024

Vinge has advised the municipality of Varberg in legal proceedings regarding a detailed development plan for a new residential area

 The detailed development plan for approximately 50 new homes in Trönningenäs, north of the city of Varberg, was adopted by the municipality on 23 February 2023. It was subsequently appealed in several stages. By decision of the Land and Environment Court of Appeal, the plan become legally binding on 2 October 2024.
October 03, 2024

Vinge has advised Egetis Therapeutics in connection with directed share issuances

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.
October 03, 2024